| Expression pattern: |
UP |
| Associated gene: |
MYH9, P-gp, MRP1, IL-2, TNF-alpha, TGF-beta |
| Associated microRNA: |
miR-138-5p |
| Biological function: |
Circ-PRMT5 promotes cisplatin resistance, cell viability, migration and invasion, inhibits apoptosis, suppresses T-cell immune response, and supports tumor growth in DDP-resistant NSCLC. |
| Molecular mechanism: |
Circ-PRMT5 acts as a ceRNA/molecular sponge for miR-138-5p to regulate MYH9 expression, thereby modulating DDP resistance and immune response in NSCLC. |
| Biological pathway or process: |
chemoresistance (promotes); drug resistance (promotes); proliferation (promotes); migration (promotes); invasion (promotes); apoptosis (inhibits); immune regulation (inhibits); ceRNA regulation (other) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; Transfection; CCK8; Annexin V/PI Flow Cytometry; Transwell Assay; ELISA; Western Blot; In Vivo Animal Model; Luciferase Reporter Assay; Bioinformatics Analysis |
| Clinical significance: |
Circ-PRMT5 may provide a promising circRNA-targeted therapy for NSCLC with DDP resistance. |
| Description: |
Circ-PRMT5 is up-regulated in DDP-resistant NSCLC tissues and cells. Its knockdown increases cisplatin sensitivity and T-cell immune response, suppresses malignant phenotypes and tumor growth, and acts mechanistically through the miR-138-5p/MYH9 axis. |
| Confidence score: |
0.6542 |